NY-DILIGENT
25.2.2021 14:02:10 CET | Business Wire | Press release
Diligent Corporation (“Diligent” or the “Company”), the modern governance company with a platform used by nearly 700,000 board directors and leaders across 19,000 clients, announced that it has signed an agreement to acquire Steele Compliance Solutions, Inc. (“Steele”), a global leader in ethics and compliance SaaS. Financial terms of the transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210225005526/en/
Steele is the trusted market leader in ethics and compliance management with more than 1,000 clients, including over 25% of the Fortune 250. Steele’s Ethics and Compliance Platform provides organizations with best-in-market capabilities for proactively managing internal and external risk. Steele’s platform leverages automation, AI-powered data, and human intelligence to help organizations navigate potential risks by providing the tools needed to proactively manage their compliance needs.
“We are excited to join forces with Steele and extend modern governance to ethics and compliance,” said Brian Stafford, CEO of Diligent. “The Steele team has an unrivaled wealth of experience and industry expertise serving compliance officers of today and tomorrow. As the market leader in ethics and compliance, Steele is core to Diligent’s strategy to leverage our strength in governance to expand our footprint in GRC and stakeholder capitalism. Together, we will offer leaders a more comprehensive C-suite and executive view of ESG risks, alongside the modern governance practices they have already implemented.”
Eric Lochner, CEO of Steele, commented: “We are passionate about delivering innovative compliance solutions to our clients. Our best-of-breed products have revolutionized how organizations big and small manage risk, giving leaders a truly integrated, holistic view of their compliance program. We’re thrilled to build on this foundation by teaming up with Diligent. Diligent’s innovative platform coupled with their like-minded dedication to their clients allows us to broaden our solution set, while ensuring our clients will still receive the high-touch, high-value experience they’ve come to expect with Steele.”
The Steele acquisition is expected to close in early March. District Capital Partners served as the exclusive financial advisor, and Willkie Farr & Gallagher LLP served as the legal advisor to Diligent. For Steele, UBS served as the financial advisor, and Goodwin Procter LLP served as the legal advisor. Bregal Sagemount acquired Steele Compliance Solutions in 2016.
Diligent yesterday also announced the highly complementary acquisition of Galvanize, a global leader in SaaS governance, risk, and compliance (GRC) software. These two acquisitions together will unite the respective leaders in governance, next-gen risk, and compliance to establish the only modern GRC SaaS platform in the market.
About Diligent Corporation
Diligent powers modern governance, enabling transformational leaders to help their organizations do the right thing. Our governance platform provides new ways for leaders to digitally transform their governance practices, from increasing board and executive effectiveness to proactively managing risk and compliance practices to integrating real-time industry and company data like cyber risk scores and board composition. Diligent empowers leaders and teams to stay connected, informed, and ahead of what’s next so they can run more successful, equitable, and sustainable organizations – and create positive change in the world.
Today, nearly 700,000 governance leaders from over 19,000 organizations and 90 countries rely on the Diligent modern governance platform. With more than 1,000 employees globally, serving both public and private sectors, we are helping organizations digitize their governance practices and transform effective governance into a long-term, competitive advantage. Diligent is backed by leading investors Insight Partners, Clearlake Capital, and Blackstone. Learn more at Diligent.com.
About Steele Compliance Solutions, Inc.
Steele is the global leader in Ethics & Compliance Management. We partner with the world’s largest, most respected, companies to deliver compliance products and services that help organizations embrace a culture of compliance while protecting their brand.
Learn more at steeleglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005526/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom